MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on January 2, 2008; DOI: 10.1124/mol.107.043299

0026-895X/08/7304-1203-1212$20.00
Mol Pharmacol 73:1203-1212, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.043299v1
73/4/1203    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Cherednichenko, G.
Right arrow Articles by Pessah, I. N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cherednichenko, G.
Right arrow Articles by Pessah, I. N.

Enhanced Excitation-Coupled Calcium Entry in Myotubes Expressing Malignant Hyperthermia Mutation R163C Is Attenuated by Dantrolene

Gennady Cherednichenko, Chris W. Ward, Wei Feng, Elaine Cabrales, Luke Michaelson, Montserrat Samso, José R. López, Paul D. Allen, and Isaac N. Pessah

Department of Molecular Biosciences, University of California, Davis, California (G.C., W.F., E.C., I.N.P.); School of Nursing, University of Maryland, Baltimore, Maryland (C.W.W., L.M.); and Department of Anesthesiology and Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, Massachusetts (J.R.L., M.S., P.D.A.)

Dantrolene is the drug of choice for the treatment of malignant hyperthermia (MH) and is also useful for treatment of spasticity or muscle spasms associated with several clinical conditions. The current study examines the mechanisms of dantrolene's action on skeletal muscle and shows that one of dantrolene's mechanisms of action is to block excitation-coupled calcium entry (ECCE) in both adult mouse flexor digitorum brevis fibers and primary myotubes. A second important new finding is that myotubes isolated from mice heterozygous and homozygous for the ryanodine receptor type 1 R163C MH susceptibility mutation show significantly enhanced ECCE rates that could be restored to those measured in wild-type cells after exposure to clinical concentrations of dantrolene. We propose that this gain of ECCE function is an important etiological component of MH susceptibility and possibly contributes to the fulminant MH episode. The inhibitory potency of dantrolene on ECCE found in wild-type and MH-susceptible muscle is consistent with the drug's clinical potency for reversing the MH syndrome and is incomplete as predicted by its efficacy as a muscle relaxant.

Received November 7, 2007; accepted December 31, 2007

Address correspondence to: Dr. Isaac N. Pessah, Department of Molecular Biosciences, School of Veterinary Medicine, One Shields Avenue, University of California, Davis, CA 95616, E-mail: inpessah{at}ucdavis.edu






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics